Rezolute (RZLT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
7 Oct, 2026Executive summary
Virtual annual meeting scheduled for Dec. 2, 2026; record-date holders as of Oct. 5, 2026 may vote on directors, auditor ratification, say-on-pay, authorized-share increase and adjournment.
Board unanimously recommends FOR all five proposals; 96,728,913 common shares were outstanding and entitled to vote on the record date.
Voting matters and shareholder proposals
Seven directors are up for election through the 2028 Annual Meeting; Grant Thornton LLP ratification covers FY ending June 30, 2027; say-on-pay is advisory.
Shareholders will vote on raising authorized common shares from 165 million to 225 million and permitting adjournment to seek additional votes for that increase.
Director election requires a plurality; auditor ratification and adjournment require a majority of votes cast; share increase requires a majority of outstanding common shares.
Board of directors and corporate governance
Seven nominees: Nevan Charles Elam, Erik Harris, Gil Labrucherie, Nerissa Kreher, Philippe Fauchet, Wladimir Hogenhuis and Young-Jin Kim; Elam is CEO and Acting Chair.
Five directors—Harris, Labrucherie, Kreher, Fauchet and Hogenhuis—were determined independent under Nasdaq rules as of June 30, 2026; Elam and Kim are not independent.
The Board held seven meetings in FY2026; each director attended at least 75% of Board and committee meetings on which they served.
Board favors combining CEO and Chair roles currently, citing Elam’s operating knowledge, but will reassess the structure as circumstances evolve.
Latest events from Rezolute
- Five proposals put board elections, executive pay, audit ratification, and share capacity to a vote.RZLT
Proxy filing - Ersodetug advances in two late-stage HI programs, with upLIFT topline results expected in 2H 2026.RZLT
Corporate presentation - Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ global potential.RZLT
Corporate presentation - Positive interim tumor HI results and ongoing FDA review for congenital HI amid rising net loss.RZLT
Q4 2026 - Late-stage antibody therapy targets refractory hypoglycemia in HI, with $1B+ market potential.RZLT
Corporate presentation - Pivotal data and regulatory milestones support dual BLA filings and strong market prospects in 2025.RZLT
Jefferies Global Healthcare Conference 2026 - Phase 3 data showed strong efficacy for ersodetug in HI; net loss narrowed as R&D costs fell.RZLT
Q3 2026 - Ersodetug advances in Phase 3 for HI, targeting a $1B+ rare disease market with FDA engagement.RZLT
Corporate presentation - Late-stage antibody therapy targets severe hypoglycemia in rare hyperinsulinism, with $1B+ potential.RZLT
Corporate presentation